AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 30739002 — intervention group
Group type: COMPARATOR
Intervention: Best available care without NIV
Number of subjects: 520
Study 29336914 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 60mg loading dose (G3)
Number of subjects: 100
Study 29336914 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 30mg loading dose (G2)
Number of subjects: 100
Study 29336914 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel 10mg loading dose (G1)
Number of subjects: 100
Study 29336914 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (G4)
Number of subjects: 100
Study 27630211 — intervention group
Group type: EXPERIMENTAL
Intervention: FABP4 levels measured in early pregnancy (median 14 weeks' gestation)
Number of subjects: 710
Study 27630211 — intervention group
Group type: EXPERIMENTAL
Intervention: FABP4 levels measured in the second trimester (median 26 weeks' gestation)
Number of subjects: 710
Study 27630211 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated second-trimester FABP4 level
Number of subjects: 710
Study 27630211 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of FABP4 to established risk factors
Number of subjects: 710
Study 24842870 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 h nurse-led one-on-one teaching session about their heart
Number of subjects: 58
Study 22952179 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary behavior modification (D)
Number of subjects: 68
Study 22952179 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise behavior modification (E)
Number of subjects: 68
Study 22952179 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dietary and physical exercise behavior modification (DE)
Number of subjects: 68
Study 22952179 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care) (C)
Number of subjects: 68
Study 19246029 — intervention group
Group type: EXPERIMENTAL
Intervention: Dialectical behaviour therapy skills training (DBT‐ST)
Number of subjects: 60
Study 19246029 — intervention group
Group type: COMPARATOR
Intervention: Standard group therapy (SGT)
Number of subjects: 60
Study 17259081 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg suprofen
Number of subjects: 11
Study 17259081 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 mg suprofen
Number of subjects: 11
Study 17259081 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 17259081 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprofen
Number of subjects: 11
Study 15088181 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/ml iodine concentration
Number of subjects: 100
Study 15088181 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg/ml iodine concentration
Number of subjects: 100
Study 15088181 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/ml iodine concentration
Number of subjects: 100
Study 15088181 — intervention group
Group type: EXPERIMENTAL
Intervention: 350 mg/ml iodine concentration
Number of subjects: 100
Study 11257152 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronan (Hyalgan) - 2 ml of 500-730 000 MW hyaluronan, 10 mg/ml in saline, one injection per week for 5 weeks
Number of subjects: 0
Study 11257152 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone acetate (Depomedrol) - 1 ml of methylprednisolone acetate, 40 mg/ml, one injection per week for 3 weeks
Number of subjects: 0
Study 11257152 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (Hyalgan and Depomedrol)
Number of subjects: 0
Study 9732167 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall (all treatments)
Number of subjects: 47
Study 8059043 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam-alfentanil-flumazenil
Number of subjects: 63
Study 8059043 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol-alfentanil
Number of subjects: 63
Study 8059043 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane-alfentanil
Number of subjects: 63
Study 3391872 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate (EA) 400 mg tid for 7-14 days
Number of subjects: 474
Study 3391872 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin base enterocoated pellets in capsules (EB enterocapsules) 500 mg tid for 7-14 days
Number of subjects: 474
Study 3391872 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin base enterocoated tablets (EB enterotablets) 500 mg tid for 7-14 days
Number of subjects: 474
Study 3391872 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin acistrate (EA)
Number of subjects: 474
Study 3391872 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin base enterocoated pellets in capsules (EB enterocapsules)
Number of subjects: 474
Study 3391872 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin base enterocoated tablets (EB enterotablets)
Number of subjects: 474
Study 31618071 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-Care Clinical Trials (POC-CT)
Number of subjects: 0
Study 31618071 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of Electronic Medical Record (EMR) and Bayesian adaptive feature
Number of subjects: 0
Study 30216846 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term PM2.5 exposure (1-year and 6-month average)
Number of subjects: 22
Study 30216846 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term PM2.5 exposure (1-year average)
Number of subjects: 22
Study 30216846 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-199a/b
Number of subjects: 22
Study 30216846 — intervention group
Group type: EXPERIMENTAL
Intervention: miR-223-3p
Number of subjects: 22
Study 30216846 — intervention group
Group type: EXPERIMENTAL
Intervention: PM2.5 ambient levels
Number of subjects: 22
Study 27049103 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal T-LysYal
Number of subjects: 83
Study 27049103 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution
Number of subjects: 83
Study 24916336 — intervention group
Group type: EXPERIMENTAL
Intervention: Perioperative chemotherapy with adriamycin plus ifosfamide
Number of subjects: 140
Study 24916336 — intervention group
Group type: COMPARATOR
Intervention: Perioperative chemotherapy with gemcitabine and docetaxel
Number of subjects: 140
Study 21035211 — intervention group
Group type: EXPERIMENTAL
Intervention: Early abciximab administration
Number of subjects: 110
Study 21035211 — intervention group
Group type: COMPARATOR
Intervention: Late abciximab administration
Number of subjects: 110
Study 19830486 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol (Visipaque, GE Healthcare, United Kingdom) administered during endovascular procedure, average 99.3 ml (range 60-180 ml)
Number of subjects: 87
Study 19830486 — intervention group
Group type: COMPARATOR
Intervention: Control group (no contrast medium administered)
Number of subjects: 87
Study 18093199 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxylapatite (CaHA)
Number of subjects: 60
Study 18093199 — intervention group
Group type: COMPARATOR
Intervention: Nonanimal-stabilized hyaluronic acid (NASHA)
Number of subjects: 60
Study 16639342 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T+ddI
Number of subjects: 373
Study 16639342 — intervention group
Group type: EXPERIMENTAL
Intervention: ddI
Number of subjects: 373
Study 16639342 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T
Number of subjects: 373
Study 16639342 — intervention group
Group type: EXPERIMENTAL
Intervention: ZDV
Number of subjects: 373
Study 16639342 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 373
Study 12745489 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (21 mg)
Number of subjects: 21
Study 12745489 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch
Number of subjects: 21
Study 11095476 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg ethinylestradiol (EE) for 7 days
Number of subjects: 2
Study 11095476 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 microg ethinylestradiol (EE) for 2 days
Number of subjects: 2
Study 11095476 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg furosemide followed by 50 mg captopril after 7 days of EE
Number of subjects: 2
Study 8810655 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmin 100 mg once daily SC
Number of subjects: 56
Study 8810655 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmin 100 mg twice a day SC
Number of subjects: 56
Study 8810655 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmin 200 mg once daily IM
Number of subjects: 56
Study 8810655 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmin (all doses)
Number of subjects: 56
Study 1350796 — intervention group
Group type: EXPERIMENTAL
Intervention: lisinopril (10‐20 mg once daily)
Number of subjects: 38
Study 1350796 — intervention group
Group type: COMPARATOR
Intervention: hydrochlorothiazide (12.5‐25 mg once daily)
Number of subjects: 38
Study 1350796 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-blocker + diuretic
Number of subjects: 38
Study 1350796 — intervention group
Group type: COMPARATOR
Intervention: beta-blocker + ACE inhibitor
Number of subjects: 38
Study 4083464 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 1.0 micrograms/kg body weight per minute in addition to 0.1 mg fentanyl/patient
Number of subjects: 20
Study 4083464 — intervention group
Group type: COMPARATOR
Intervention: High-dose fentanyl anaesthesia (mean: 2.45 mg fentanyl/patient)
Number of subjects: 20
Study 31221297 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey protein (WP) supplementation (35 g daily)
Number of subjects: 26
Study 31221297 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 26
Study 30462790 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-pharmacological interventions
Number of subjects: 32
Study 28202846 — intervention group
Group type: EXPERIMENTAL
Intervention: MFGM tablets (1 g MFGM/d)
Number of subjects: 22
Study 28202846 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 22
Study 24670140 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g of sucrose per kg of body mass per hour of recovery (g.kg‐1.h‐1)
Number of subjects: 0
Study 24670140 — intervention group
Group type: COMPARATOR
Intervention: 0.3 g of sucrose per kg of body mass per hour of recovery (g.kg‐1.h‐1)
Number of subjects: 0
Study 24670140 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g of sucrose per kg of body mass per hour of recovery (g.kg‐1.h‐1) with 0.4 g.kg‐1.h‐1 whey protein hydrolysate
Number of subjects: 0
Study 22812907 — intervention group
Group type: COMPARATOR
Intervention: hCG administration 35-36 h prior to oocyte retrieval (Group A)
Number of subjects: 125
Study 22812907 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG administration delayed by 1 day (Group B)
Number of subjects: 125
Study 22812907 — intervention group
Group type: EXPERIMENTAL
Intervention: hCG administration delayed by 2 days (Group C)
Number of subjects: 125
Study 20116841 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg ulipristal acetate
Number of subjects: 2221
Study 20116841 — intervention group
Group type: COMPARATOR
Intervention: 1.5 mg levonorgestrel
Number of subjects: 2221
Study 20116841 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of ulipristal acetate
Number of subjects: 2221
Study 20116841 — intervention group
Group type: COMPARATOR
Intervention: Meta-analysis of levonorgestrel
Number of subjects: 2221
Study 17573494 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise challenge test (ECT)
Number of subjects: 55
Study 16640634 — intervention group
Group type: EXPERIMENTAL
Intervention: Harvard cement
Number of subjects: 45
Study 16640634 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuji PLUS cement
Number of subjects: 45
Study 16640634 — intervention group
Group type: EXPERIMENTAL
Intervention: Variolink II cement
Number of subjects: 45
Study 16640634 — intervention group
Group type: COMPARATOR
Intervention: Negative control group (gutta‐percha and sealer)
Number of subjects: 45
Study 16640634 — intervention group
Group type: COMPARATOR
Intervention: Positive control group (gutta‐percha only)
Number of subjects: 45
Study 12919339 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethosuximide
Number of subjects: 0
Study 12919339 — intervention group
Group type: EXPERIMENTAL
Intervention: Valproate
Number of subjects: 0
Study 12919339 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Number of subjects: 0
Study 12919339 — intervention group
Group type: EXPERIMENTAL
Intervention: Eight drugs for primary generalized tonic-clonic seizures
Number of subjects: 0
Study 10970716 — intervention group
Group type: EXPERIMENTAL
Intervention: High fatty acid deficiency ratings
Number of subjects: 97
Study 10970716 — intervention group
Group type: EXPERIMENTAL
Intervention: High fatty acid deficiency ratings (males)
Number of subjects: 97
Study 10970716 — intervention group
Group type: COMPARATOR
Intervention: Few clinical signs of fatty acid deficiency
Number of subjects: 97
Study 10970716 — intervention group
Group type: EXPERIMENTAL
Intervention: High fatty acid deficiency ratings (females)
Number of subjects: 97
Study 8973872 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenoxicam 20 mg
Number of subjects: 80
Study 8973872 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 1462990 — intervention group
Group type: EXPERIMENTAL
Intervention: ALG 15 mg/kg just before transplant surgery, ALG 12 mg/kg the first day after transplant, followed by four doses of 10 mg/kg on alternate days
Number of subjects: 140
Study 1462990 — intervention group
Group type: COMPARATOR
Intervention: OKT3 5 mg just before transplant, followed by four doses of 5 mg/d
Number of subjects: 140
Study 1462990 — intervention group
Group type: EXPERIMENTAL
Intervention: ALG group
Number of subjects: 140
Study 1462990 — intervention group
Group type: COMPARATOR
Intervention: OKT3 group
Number of subjects: 140
Study 4028871 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymecycline 300 mg
Number of subjects: 8
Study 4028871 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline 100 mg
Number of subjects: 8
Study 4028871 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymecycline
Number of subjects: 8
Study 4028871 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 8
Study 31856495 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% ropivacaine
Number of subjects: 60
Study 31856495 — intervention group
Group type: COMPARATOR
Intervention: 0.5% bupivacaine
Number of subjects: 60
Study 30367243 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (20 min, 2 mA)
Number of subjects: 20
Study 30367243 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 20
Study 28535959 — intervention group
Group type: EXPERIMENTAL
Intervention: 1ml/kg of 0.25% caudal‐bupivacaine and 1mg/kg rectal‐diclofenac
Number of subjects: 90
Study 28535959 — intervention group
Group type: COMPARATOR
Intervention: 1ml/kg of 0.25% caudal‐bupivacaine and 30mg/kg rectal paracetamol
Number of subjects: 90
Study 28535959 — intervention group
Group type: COMPARATOR
Intervention: 1ml/kg of 0.25% caudal‐bupivacaine
Number of subjects: 90
Study 25495835 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia educational tools
Number of subjects: 43
Study 25495835 — intervention group
Group type: COMPARATOR
Intervention: Conventional 'study day' teaching
Number of subjects: 43
Study 23443282 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 5 cm H2O
Number of subjects: 14
Study 23443282 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 15 cm H2O
Number of subjects: 14
Study 23443282 — intervention group
Group type: COMPARATOR
Intervention: Comparison between PEEP 15 cm H2O and PEEP 5 cm H2O
Number of subjects: 14
Study 21659058 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium (6x419 mg Mg chloride/capsule per day for a month)
Number of subjects: 45
Study 21659058 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 45
Study 21659058 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium
Number of subjects: 45
Study 18450851 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphtheria-tetanus-acellular pertussis immunization
Number of subjects: 191
Study 18450851 — intervention group
Group type: COMPARATOR
Intervention: Control (no immunization)
Number of subjects: 191
Study 16555167 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypericum extract STW3-VI (900 mg)
Number of subjects: 388
Study 16555167 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20 mg)
Number of subjects: 388
Study 16555167 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 388
Study 16279863 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine monotherapy
Number of subjects: 0
Study 16279863 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine combined with fluoxetine
Number of subjects: 0
Study 16279863 — intervention group
Group type: COMPARATOR
Intervention: Quetiapine monotherapy
Number of subjects: 0
Study 16279863 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone added to ongoing therapy
Number of subjects: 0
Study 10996349 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone supplementation (1 or 2 tablets per day)
Number of subjects: 66
Study 10996349 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone supplementation (1 tablet per day)
Number of subjects: 66
Study 10996349 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66
Study 9327191 — intervention group
Group type: EXPERIMENTAL
Intervention: Zopiclone 5 mg
Number of subjects: 135
Study 9327191 — intervention group
Group type: COMPARATOR
Intervention: Propiomazine 25 mg
Number of subjects: 135
Study 1337553 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin, 10 mg/Kg/day per os once daily for 3 days or 10 mg/Kg/day on day 1 and 5 mg/Kg/day on days 2-5 (77 patients)
Number of subjects: 151
Study 1337553 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin, 50 mg/Kg/day thrice daily for at least 7 days (74 patients)
Number of subjects: 151
Study 3903732 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifactorial prevention intervention
Number of subjects: 49781
Study 3903732 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49781
Study 30545923 — intervention group
Group type: COMPARATOR
Intervention: Azacitidine
Number of subjects: 160
Study 30545923 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide + Azacitidine (75mg/m2/d days 1 to 5 with lenalidomide 10mg days 1‐21 of 28‐day cycle from cycle 3)
Number of subjects: 160
Study 30545923 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide + Azacitidine
Number of subjects: 160
Study 30545923 — intervention group
Group type: EXPERIMENTAL
Intervention: Both arms (Azacitidine and Lenalidomide + Azacitidine)
Number of subjects: 160
Study 30566442 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of ARV ADR defining criteria
Number of subjects: 52
Study 30566442 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of the system's purpose
Number of subjects: 52
Study 30566442 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of the reporting process
Number of subjects: 52
Study 30566442 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of ARV ADRs following client complaints
Number of subjects: 52
Study 30566442 — intervention group
Group type: EXPERIMENTAL
Intervention: Enquiry about clients' medication response
Number of subjects: 52
Study 30566442 — intervention group
Group type: EXPERIMENTAL
Intervention: Cited non-feedback from MCAZ for underreporting
Number of subjects: 52
Study 30566442 — intervention group
Group type: EXPERIMENTAL
Intervention: Inadequate ARV ADR identification skills
Number of subjects: 52
Study 30566442 — intervention group
Group type: EXPERIMENTAL
Intervention: Availability of reporting forms
Number of subjects: 52
Study 30566442 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic decisions made from ARV ADRs
Number of subjects: 52
Study 30566442 — intervention group
Group type: EXPERIMENTAL
Intervention: Usefulness score of the pharmacovigilance system
Number of subjects: 52
Study 30566442 — intervention group
Group type: EXPERIMENTAL
Intervention: Case detection rate
Number of subjects: 52
Study 30566442 — intervention group
Group type: EXPERIMENTAL
Intervention: Data quality
Number of subjects: 52
Study 26719232 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus docetaxel (SOC + Doc)
Number of subjects: 2962
Study 26719232 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care plus zoledronic acid (SOC + ZA)
Number of subjects: 2962
Study 26719232 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care with both zoledronic acid and docetaxel (SOC + ZA + Doc)
Number of subjects: 2962
Study 26719232 — intervention group
Group type: COMPARATOR
Intervention: Standard of care only (SOC-only)
Number of subjects: 2962
Study 25230681 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary fibre intake
Number of subjects: 1114
Study 25230681 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of low saturated fat intake and high cardiorespiratory fitness
Number of subjects: 1114
Study 22768458 — intervention group
Group type: EXPERIMENTAL
Intervention: O packed cell (group 1)
Number of subjects: 100
Study 22768458 — intervention group
Group type: EXPERIMENTAL
Intervention: O dried packed cell (group 2)
Number of subjects: 100
Study 22768458 — intervention group
Group type: EXPERIMENTAL
Intervention: O packed cell (group 3)
Number of subjects: 100
Study 22768458 — intervention group
Group type: COMPARATOR
Intervention: Infant isogroup (group 4)
Number of subjects: 100
Study 22768458 — intervention group
Group type: COMPARATOR
Intervention: All groups
Number of subjects: 100
Study 22768458 — intervention group
Group type: EXPERIMENTAL
Intervention: Infants with two transfusions
Number of subjects: 100
Study 20146649 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine
Number of subjects: 15
Study 20146649 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 17010507 — intervention group
Group type: EXPERIMENTAL
Intervention: Retropubic route (RPR)
Number of subjects: 88
Study 17010507 — intervention group
Group type: COMPARATOR
Intervention: Transobturator route (TOR)
Number of subjects: 88
Study 17010507 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RPR and TOR
Number of subjects: 88
Study 16269589 — intervention group
Group type: COMPARATOR
Intervention: Desipramine treatment
Number of subjects: 0
Study 16269589 — intervention group
Group type: EXPERIMENTAL
Intervention: PD+OH group
Number of subjects: 0